Multi-functional particles and methods of using the same

1. A method of delivering two or more therapeutic agents to a target, the method comprising:

administering a micelle to the target, wherein the micelle comprises poly(lactide-co-glycolide)-graft-polyethylenimine (PLGA-g-PEI (PgP)) and the two or more therapeutic agents,

wherein the two or more therapeutic agents comprise an antiproliferative drug and an antithrombotic drug;

wherein the micelle has an interior hydrophobic core and a shell having a hydrophilic exterior surface;

wherein PLGA-g-PEI forms the micelle, and at least a portion of PLGA of PLGA-g-PEI forms at least a portion of the interior hydrophobic core and at least a portion of PEI of PLGA-g-PEI forms at least a portion of the hydrophilic exterior surface of the shell;

wherein the micelle comprises 2-7 molecules of PLGA grafted to branched chain PEI with the PLGA having a molecular weight of 20 kDaltons to 100 kDaltons; and

wherein the micelle has a diameter in a range of about 100 nm to about 300 nm, thereby delivering the two or more therapeutic agents to the target.

2. The method of claim 1 , wherein one of the two or more therapeutic agents is bound to a portion of the hydrophilic exterior surface of the shell and another of the two or more therapeutic agents is present in the interior hydrophobic core of the micelle.

3. The method of claim 2 , wherein the therapeutic agent present in the interior hydrophobic core is sirolimus or paclitaxel and the therapeutic agent bound to the portion of the hydrophilic exterior surface of the shell is heparin.

4. The method of claim 1 , further comprising at least one nucleic acid that is present on a portion of the hydrophilic exterior surface of the shell.

5. The method of claim 1 , wherein the micelle further comprises at least one targeting moiety that is covalently conjugated to a portion of the hydrophilic exterior surface of the shell.

6. The method of claim 1 , wherein the micelle is stable in an aqueous solution, at −20° C. for at least 6 months.

7. The method of claim 1 , wherein the PEI in the PLGA-g-PEI has a molecular weight in a range of about 2 kDaltons to about 35 kDaltons.

8. The method of claim 1 , wherein the PLGA-g-PEI has a molecular weight in a range of about 30 kDaltons to about 500 kDaltons.

9. The method of claim 1 , wherein the PLGA-g-PEI has a hydrophobic lipophilic balance in a range of about 4 to about 12.

10. The method of claim 1 , wherein the micelle is present in a pharmaceutical composition and administering the micelle to the target comprises administering the pharmaceutical composition to a subject.

11. The method of claim 10 , wherein the pharmaceutical composition further comprises a cryoprotectant.

12. The method of claim 10 , wherein 1 mL of the pharmaceutical composition comprises about 1 mg PgP, and the two or more therapeutic agents are each present in an amount of about 25 μg per mL of the pharmaceutical composition to about 1,000 μg per mL of the pharmaceutical composition.

13. The method of claim 10 , wherein administering the pharmaceutical composition to the subject comprises inhibiting smooth muscle cell proliferation in vasculature of the subject and/or inhibiting extracellular membrane (ECM) production and/or deposition in vasculature of the subject.

14. The method of claim 1 , wherein the at least two therapeutic agents are released from the micelle for at least one week.

15. The method of claim 1 , wherein the micelle comprises 3-7molecules of PLGA grafted to about 25 kDa branched chain PEI.

16. The method of claim 1 , wherein the micelle comprises 2-5 molecules of about 25 kDa PLGA grafted to about 25 kDa branched chain PEI.

17. The method of claim 1 , wherein the micelle comprises 2-5 molecules of about 50 kDa PLGA grafted to about 25 kDa branched chain PEI.

18. A method of increasing the therapeutic efficacy of at least one therapeutic agent in a subject, the method comprising:

administering a micelle to the subject, wherein the micelle comprises poly(lactide-co-glycolide)-graft-polyethylenimine (PLGA-g-PEI (PgP)) and at least two therapeutic agents,

wherein the micelle has an interior hydrophobic core and a shell having a hydrophilic exterior surface;

wherein PLGA-g-PEI forms the micelle and has a molecular weight in the range of about 50 kDaltons to about 90 kDaltons, and at least a portion of PLGA of PLGA-g-PEI forms at least a portion of the interior hydrophobic core and at least a portion of PEI of PLGA-g-PEI forms at least a portion of the hydrophilic exterior surface of the shell;

wherein the PLGA in the PLGA-g-PEI has a molecular weight in a range of 40 kDaltons to about 70 kDaltons and the PLGA is grafted to the PEI of the PgP; and

wherein the micelle has a diameter in a range of about 100 nm to about 300 nm, thereby increasing the therapeutic efficacy of the at least one therapeutic agent in the subject.

19. A micelle comprising poly(lactide-co-glycolide)-graft-polyethylenimine (PLGA-g-PEI (PgP)) and at least two therapeutic agents,

wherein the micelle has an interior hydrophobic core and a shell having a hydrophilic exterior surface;

wherein PLGA-g-PEI forms the micelle, and at least a portion of PLGA of PLGA-g-PEI forms at least a portion of the interior hydrophobic core and at least a portion of PEI of PLGA-g-PEI forms at least a portion of the hydrophilic exterior surface of the shell;

wherein the at least two therapeutic agents comprise an antiproliferative drug and an antithrombotic drug;

wherein the micelle has a diameter in a range of about 100 nm to about 300 nm;

wherein the micelle comprises 3-5 molecules of PLGA grafted to branched chain PEI with the PLGA having a molecular weight of about 50 kDaltons and the branched chain PEI having a molecular weight of about 25 kDaltons; and

wherein the antiproliferative drug is present in the interior hydrophobic core of the micelle and wherein the antithrombotic drug is present on a portion of the hydrophilic exterior surface of the shell.

20. A method of treating and/or preventing cardiovascular disease, restenosis, and/or thrombosis in a subject, the method comprising:

administering the micelle of claim 19 to the subject, thereby treating and/or preventing cardiovascular disease, restenosis, and/or thrombosis in the subject.